Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma
Details
Publication Year 2024-01,Volume 6,Issue #1,Page vdae041
Journal Title
Neuro-Oncology Advances
Publication Type
Research article
Abstract
BACKGROUND: Liquid biopsy based on circulating tumor DNA (ctDNA) is a novel tool in clinical oncology, however, its use has been limited in glioma to date, due to low levels of ctDNA. In this study, we aimed to demonstrate that sequencing techniques optimized for liquid biopsy in glioma patients can detect ctDNA in plasma with high sensitivity and with potential clinical utility. METHODS: We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500. RESULTS: Glioma-derived ctDNA mutations were detected in 93.8% of plasma samples. 25% of all mutations detected were observed in plasma only. Mutations of the mismatch repair (MMR) genes MSH2 and MSH6 were the most frequent circulating gene alterations seen after temozolomide treatment and were frequently observed to appear in plasma prior to their appearance in tumor tissue at the time of surgery for recurrence. CONCLUSIONS: This pilot study suggests that plasma ctDNA in glioma is feasible and may provide sensitive and complementary information to tissue biopsy. Furthermore, plasma ctDNA detection of new MMR gene mutations not present in the initial tissue biopsy may provide an early indication of the development of chemotherapy resistance. Additional clinical validation in larger cohorts is needed.
Publisher
Oxford University Press
Keywords
biomarkers; ctDNA; glioblastoma; glioma; liquid biopsy
Department(s)
Laboratory Research
Open Access at Publisher's Site
https://doi.org/10.1093/noajnl/vdae041
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-11 01:41:17
Last Modified: 2024-07-11 01:48:04

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙